Skip to main content

Table 2 Patient, diagnostic, and pathologic characteristics of post-RYGB patients undergoing pancreaticoduodenectomy in reviewed cases (N = 26)

From: Reconstruction options following pancreaticoduodenectomy after Roux-en-Y gastric bypass: a systematic review

Parameter

Proportion or median

Percentage (%) or IQR

Patient demographics

 Sex (female)

12/15

80

 Age (years)

54

52–61

 Years from RYGB*

5

2–10

Presenting complaint**

 Pain

18/26

69.2

 Jaundice

14/26

53.8

 Weight loss

9/26

34.6

 Nausea/vomiting

5/26

19.2

 Incidental finding

4/26

15.4

 Diarrhea

2/26

7.7

 Fever/chills

1/26

3.9

Preoperative diagnostic modality**

 CT

26/26

100

 PTC

9/26

34.6

 Percutaneous biopsy

3/26

11.5

 Endoscopic biopsy

2/26

7.7

 US

1/26

3.9

 MRCP

1/26

3.9

Pathologic diagnosis

 PDAC

14/26

53.8

 NET

3/26

11.5

 CP

3/26

11.5

 FDBDF

2/26

7.7

 IPMN

1/26

3.9

 Duodenal Ca

1/26

3.9

 Ampullary Ca

1/26

3.9

  1. IQR interquartile range, RYGB Roux-en-Y Gastric Bypass, PDAC pancreatic ductal adenocarcinoma, NET neuroendocrine tumor, FDBDF focal distal bile duct fibrosis, CP chronic pancreatitis, IPMN intraductal papillary mucinous neoplasm, CT computed tomography, US ultrasound, MRCP magnetic resonance cholangiopancreatography, PTC percutaneous transhepatic cholangiography
  2. *Only 11 cases with reported RYGB details
  3. **Possible for one patient to have multiple presenting symptoms or diagnostic modalities